KLRG1 and glioma: Tumor and peripheral blood samples from 32 glioma patients (WHO 2021 classification, grades II-IV) were analyzed by flow cytometry to assess ILC subsets and immunecheckpoint molecules (PD-1, CTLA-4, KLRG1).